Venture capitalists return to biotechnology, life sciences

09/25/2012 | Reuters

Venture-backed investments in biotechnology rose by 24% to $4.82 billion last year over 2010 figures, and venture firms are raising more funds this year dedicated to life sciences, biotech and medicine. Established drugmakers seeking refilled pipelines are increasingly investing in early-stage research, and some have set up their own venture funds. Regulations and policies that speed drug approvals could also accelerate returns and attract more funds, investors say.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID